Analysts Are Bullish on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), Integra Lifesciences (IART)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bausch + Lomb Corporation (BLCO – Research Report), Integra Lifesciences (IART – Research Report) and United Therapeutics (UTHR – Research Report) with bullish sentiments.

Bausch + Lomb Corporation (BLCO)

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation today and set a price target of $23.00. The company’s shares closed last Wednesday at $16.60.

According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of 12.6% and a 62.6% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, GE Healthcare Technologies Inc, and Inspire Medical Systems.

The word on The Street in general, suggests a Hold analyst consensus rating for Bausch + Lomb Corporation with a $17.75 average price target, representing an 11.4% upside. In a report issued on February 9, RBC Capital also assigned a Buy rating to the stock with a $19.00 price target.

See the top stocks recommended by analysts >>

Integra Lifesciences (IART)

Wells Fargo analyst Vik Chopra maintained a Buy rating on Integra Lifesciences today and set a price target of $49.00. The company’s shares closed last Wednesday at $44.75.

According to TipRanks.com, Chopra is a 3-star analyst with an average return of 4.5% and a 64.7% success rate. Chopra covers the Healthcare sector, focusing on stocks such as Alphatec Holdings, Globus Medical, and NeuroPace.

Integra Lifesciences has an analyst consensus of Hold, with a price target consensus of $46.33.

United Therapeutics (UTHR)

Wells Fargo analyst Tiago Fauth maintained a Buy rating on United Therapeutics today and set a price target of $309.00. The company’s shares closed last Wednesday at $219.18.

According to TipRanks.com, Fauth has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -7.0% and a 38.1% success rate. Fauth covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Aerovate Therapeutics, and Pliant Therapeutics.

United Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $304.00, representing a 38.4% upside. In a report released today, TD Cowen also maintained a Buy rating on the stock with a $270.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BLCO:

• BLCO Earnings: Bausch + Lomb Outperforms in Q4, Shares Jump
• Bausch Health price target lowered to $14 from $16 at Jefferies
• Bausch + Lomb margin expansion delayed until 2025, says Deutsche Bank
• Bausch + Lomb CFO says 2024 ‘an investment year’
• Bausch + Lomb announces FDA approval of TENEO Excimer Laser Platform